Concurrent Indolent Lymphomas in Diffuse Large B-Cell Lymphoma Do Not Worsen Clinical Outcomes
Patients with concurrent diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma were more likely to have germinal center B-cell-like DLBCL.
Patients with concurrent diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma were more likely to have germinal center B-cell-like DLBCL.
Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
Hemolytic anemia and immune thrombocytopenic purpura were the most common complications of immune checkpoint inhibitor therapy.
No association was found between number of organs involved and progression-free or overall survival in patients with amyloidosis who underwent transplant.
Patients who developed cerebrovascular disease following allogeneic hematopoietic stem cell transplantation experienced decreased survival.
Relapse risk increased with cumulative granulocyte colony-stimulating factor dosage but appeared to level out at approximately 75 mg/kg to 100 mg/kg.
Thromboprophylaxis with rivaroxaban was not found to have benefit in ambulatory patients receiving systemic cancer therapy, according to a study published in the New England Journal of Medicine.
Loss of intestinal bacterial diversity in patients undergoing AHCT may be comparable to reductions experienced by patients undergoing alloHCT.
Stringent CR criteria may not predict clinical outcomes for patients with MM.